Lucas G. Chase
Research Subjects
Lucas G. Chase has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Brian Agnew
Life Technologies
1 shared publication Courtenay Hart
Life Technologies, Eugene, OR, USA
1 shared publicationDavid Majewski
1 shared publicationJeff Grinager
1 shared publicationMahbod Hajivandi
1 shared publication- Mahendra S. Rao
Life Technologies, Frederick, MD 21704, USA
1 shared publication
Latest Publications
- 1 May 2011
- Published by SAGE Publications in Genetic Engineering & Biotechnology News
- Vol. 31 (9) , 26-27
Human Stem Cell-Derived In Vitro Model
- 1 May 2011
- Published by SAGE Publications in Genetic Engineering & Biotechnology News
- Vol. 31 (9) , 26-27
Human Stem Cell-Derived In Vitro Model
- 11 February 2011
- Published by Springer Nature
- Vol. 698, 459-484
Metabolic Labeling and Click Chemistry Detection of Glycoprotein Markers of Mesenchymal Stem Cell Differentiation
Human mesenchymal stem cells (hMSCs) are multipotent stem cells that can differentiate into a variety of cell types in vitro including osteoblasts, adipocytes, and chondrocytes. Here we apply a metabolic labeling approach to characterize changes in cellular glycoprotein expression during hMSC differentiation and to identify glycoprotein markers unique to differentiated cell types. The two-step labeling method involves the metabolic incorporation of unnatural azido-modified sugars into protein glycans and subsequent ligation with fluorescent azide-reactive detection probes utilizing the copper (I)-catalyzed cycloaddition reaction between azides and alkynes, or “click” chemistry. Metabolic labeling of cell surface O-linked or sialic acid-containing glycoproteins, or intracellular O-GlcNAc-modified proteins was accomplished by feeding cells the tetraacetylated azide-modified sugar precursors, GalNAz, ManNAz, or GlcNAz, respectively, for 48–72 h prior to harvesting the cells. The cells were then lysed, and protein extracts were reacted with a fluorescent alkyne detection probe. Labeled glycoproteins were analyzed by 1D and 2D gel electrophoresis and detected by fluorescence imaging. Our results demonstrate highly sensitive labeling of O-linked, sialic acid-containing, and O-GlcNAc modified proteins in all cell types without affecting cell growth or morphology. Selective labeling of sialic acid-containing glycoproteins by ManNAz was validated by loss of labeling following digestion with sialidase A. Significant changes in cellular glycoprotein profiles were seen upon differentiation into different cell types, and several putative glycoprotein markers were identified by MALDI peptide fingerprinting. One of these identified proteins, Galectin 1, is validated and shown for the first time to be posttranslationally modified by O-glycosylation, most likely by O-linked N-acetylglucosamine (O-GlcNAc).
- 11 February 2011
- Published by Springer Nature
- Vol. 698, 459-484
Metabolic Labeling and Click Chemistry Detection of Glycoprotein Markers of Mesenchymal Stem Cell Differentiation
Human mesenchymal stem cells (hMSCs) are multipotent stem cells that can differentiate into a variety of cell types in vitro including osteoblasts, adipocytes, and chondrocytes. Here we apply a metabolic labeling approach to characterize changes in cellular glycoprotein expression during hMSC differentiation and to identify glycoprotein markers unique to differentiated cell types. The two-step labeling method involves the metabolic incorporation of unnatural azido-modified sugars into protein glycans and subsequent ligation with fluorescent azide-reactive detection probes utilizing the copper (I)-catalyzed cycloaddition reaction between azides and alkynes, or “click” chemistry. Metabolic labeling of cell surface O-linked or sialic acid-containing glycoproteins, or intracellular O-GlcNAc-modified proteins was accomplished by feeding cells the tetraacetylated azide-modified sugar precursors, GalNAz, ManNAz, or GlcNAz, respectively, for 48–72 h prior to harvesting the cells. The cells were then lysed, and protein extracts were reacted with a fluorescent alkyne detection probe. Labeled glycoproteins were analyzed by 1D and 2D gel electrophoresis and detected by fluorescence imaging. Our results demonstrate highly sensitive labeling of O-linked, sialic acid-containing, and O-GlcNAc modified proteins in all cell types without affecting cell growth or morphology. Selective labeling of sialic acid-containing glycoproteins by ManNAz was validated by loss of labeling following digestion with sialidase A. Significant changes in cellular glycoprotein profiles were seen upon differentiation into different cell types, and several putative glycoprotein markers were identified by MALDI peptide fingerprinting. One of these identified proteins, Galectin 1, is validated and shown for the first time to be posttranslationally modified by O-glycosylation, most likely by O-linked N-acetylglucosamine (O-GlcNAc).
- 11 February 2011
- Published by Springer Nature
- Vol. 698, 3-8
Mesenchymal Stem Cell Assays and Applications
Research on mesenchymal stem cells (MSC) is progressing with increasing popularity. Currently there are a significant number of clinical trials exploring the use of MSCs for the treatment of various diseases including graft-versus-host disease, Crohn’s disease, myocardial infarction, stroke, bone defects, diabetes, and wound repair (www.clinicaltrails.gov). At the same time, there are questions associated with MSCs in terms of their isolation, culture expansion, phenotype, multipotential differentiation, and transplantation efficiency. This chapter outlines the current status of the field and emphasizes the need for clearly defined protocols to better define the function and use of MSCs in cell therapy.
- 11 February 2011
- Published by Springer Nature
- Vol. 698, 3-8
Mesenchymal Stem Cell Assays and Applications
Research on mesenchymal stem cells (MSC) is progressing with increasing popularity. Currently there are a significant number of clinical trials exploring the use of MSCs for the treatment of various diseases including graft-versus-host disease, Crohn’s disease, myocardial infarction, stroke, bone defects, diabetes, and wound repair (www.clinicaltrails.gov). At the same time, there are questions associated with MSCs in terms of their isolation, culture expansion, phenotype, multipotential differentiation, and transplantation efficiency. This chapter outlines the current status of the field and emphasizes the need for clearly defined protocols to better define the function and use of MSCs in cell therapy.